MDMA is expanding into eating disorders. The rationale is trauma, and the evidence is early.

MDMA-assisted therapy is moving beyond PTSD into eating disorders, on the logic that trauma underlies many of these conditions. It is a real research direction, but not a first, and the evidence so far is a secondary analysis and a few early trials. That is the right place to set expectations.

MDMA-assisted therapy, stalled at the FDA in post-traumatic stress disorder, is quietly extending into a new set of indications: eating disorders. The rationale is the well-documented overlap between trauma and disordered eating, and the direction is real. It is also early, indirect, and not the novelty it is sometimes presented as. A reported new trial in bulimia would extend a research line that already includes anorexia and binge eating disorder rather than opening one.

The rationale

Eating disorders carry high rates of comorbid trauma and PTSD, and the bridge from one to the other is mechanistic. If MDMA-assisted therapy helps PTSD by allowing patients to process trauma with reduced fear and defensiveness, the reasoning goes, it might help eating disorders in the substantial share of patients for whom trauma is a driver. That is a coherent hypothesis, and it is the basis for the entire line of work.

What the evidence actually is

The strongest existing signal is a secondary analysis rather than a dedicated trial. In the large MDMA-for-PTSD program, MDMA-assisted therapy was associated with a significant reduction in eating-disorder symptoms, measured by a validated screening questionnaire, compared with placebo plus the same therapy. That is suggestive, but it has a clear ceiling: it was measured in PTSD patients who happened to have eating-disorder symptoms, using a screening tool, not in patients carrying a formal eating-disorder diagnosis, a limitation the study’s own authors noted.

Beyond that, dedicated trials already exist. A multi-site study of MDMA-assisted psychotherapy for eating disorders is enrolling patients with anorexia nervosa, restricting type, and with binge eating disorder, using a structure of preparatory sessions, MDMA sessions, and integrative therapy that includes a caregiver. So MDMA for eating disorders is already a clinical-stage research direction. A reported Phase 1 trial in bulimia would add a third subtype to that effort.

Why this calls for a high evidence bar

Several cautions apply at once. The direction is not new, so framing any single trial as the first clinical test of MDMA in eating disorders is inaccurate. The best available evidence is indirect, drawn from a screening instrument in a PTSD population rather than a powered trial in diagnosed patients, and the dedicated trials are early-phase and small. Eating disorders are serious, high-mortality illnesses with difficult treatment and high relapse rates, and the field has watched many promising approaches fail to hold up, so the bar for believing a new one should be high. MDMA itself remains in regulatory limbo after the 2024 rejection of its PTSD application, which means an eating-disorder indication sits even earlier in the pipeline and inherits the same molecule-level obstacles, the Schedule I status, the drug-plus-therapy delivery model, and the trial-conduct and consent questions the desk has covered.

There is also a population-specific safety consideration. MDMA has cardiovascular and metabolic effects, and patients with eating disorders, particularly anorexia, can be medically fragile. The existing trials require demonstrated medical stability before enrollment, which is the appropriate gate, and it underscores that this is a population where safety screening is not a formality.

The pattern

This fits MDMA’s broader expansion beyond PTSD, alongside the drug-interaction questions and the next-generation analogue work the desk has tracked, and it fits the wider psychedelic pattern of molecules being pushed into adjacent indications on mechanistic rationale, frequently through academic and nonprofit research, ahead of regulatory clarity. Psilocybin is moving into pain and OCD, lysergide into anxiety and depression, and MDMA into eating disorders. The common thread is hypothesis-driven indication expansion running well ahead of the data.

The frame

MDMA in eating disorders is a rational research direction grounded in the real link between trauma and disordered eating, but it is early, the evidence is indirect, and it is not the first of its kind. The honest reading is that the field is testing whether MDMA’s trauma-processing effect translates to a notoriously treatment-resistant group of illnesses, a worthwhile question with the interest currently far ahead of the evidence. The signal to track is whether the dedicated trials in diagnosed patients produce direct results, not whether a secondary analysis hints at them. For a class of illness where options are limited and relapse is common, a new mechanistic approach is worth watching, with a high evidence bar and a clear memory of how often eating-disorder treatments have promised more than they delivered.